Recombinant Human IL-6R alpha Protein, CF

Recombinant Human IL-6R alpha (Catalog # 227-SR/CF) enhances the IL-6 activity on the M1 mouse myeloid leukemia cell line. The ED50 for this effect is 5-15 ng/mL.

1 μg/lane of Recombinant Human IL‑6R alpha was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a single band at 45‑50 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IL-6R alpha Protein, CF Summary

• Details of Functionality: Measured by its ability to enhance the IL-6 activity on M1 mouse myeloid leukemia cells. Saito, T. et al. (1991) J. Immunol. 147:168. The ED₅₀ for this effect is 5-15 ng/mL.
• Source: Spodoptera frugiperda, Sf 21 (baculovirus)-derived human IL-6R alpha protein
  Leu20-Asp358
• Accession #: P08887.1
• N-terminal Sequence: Leu20
• Protein/Peptide Type: Recombinant Proteins
• Gene: IL6R
• Purity: >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 38 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 45-50 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-6R alpha Protein, CF

• CD126
• gp80
• IL-6 R alpha
• IL6Q
• IL6R alpha
• IL-6R alpha
• IL6R
• IL-6R-1
• IL6RA
• IL-6Ra
• IL6RQ
• interleukin 6 receptor

Background

The multifunctional factor interleukin 6 (IL-6) exerts its activities through binding to a high-affinity receptor complex consisting of two membrane glycoproteins: an 80 kDa component receptor that binds IL-6 with low affinity (IL-6R alpha ) and a signal-transducing component of 130 kDa (gp130) that does not bind IL-6 by itself, but is required for high-affinity binding of IL-6 by the complex. Both components of the receptor complex, IL-6R alpha and gp130 have been cloned, sequenced, and expressed (1-4).

A soluble form of the IL-6R alpha has been found in the urine of healthy adult humans (5). This soluble receptor apparently arises from proteolytic cleavage of membrane-bound IL-6R alpha . No naturally-occurring mRNA encoding a truncated form of the IL-6R alpha has been reported. Soluble forms of human and murine IL-6R alpha s have been constructed, however, by insertion of termination codons into the regions of the IL-6R alpha cDNAs encoding the external portions of the receptors and prior to the transmembrane domains. These soluble receptors have been expressed in COS-7 and CHO cells and have been shown to bind to IL-6 in solution and to augment the activity of IL-6 as a result of the binding of the IL-6/IL-6R alpha complex to membrane-bound gp130 (6, 7).

1. Yamasaki et al. (1988) Science 241:825.
2. Baumann et al. (1990) J. Biol. Chem. 265:19853.
3. Hibi et al. (1990) Cell 63:1149.
4. Schooltink et al. (1991) Eur. J. Biochem. 277:659.
5. Novick et al. (1989) J. Exp. Med. 170:1409.
6. Yasukawa et al. (1990) J. Biochem. 108:673.
7. Saito et al. (1991) J. Immunology 147:168.

Publications for IL-6R alpha (227-SR/CF)(41)

Publications using 227-SR/CF

• Y Nishikawa, Y Tomotake, H Kawano, K Naruishi, JI Kido, Y Hiroshima, A Murakami, T Ichikawa, H Yumoto Effects of Candidalysin Derived from Candida albicans on the Expression of Pro-Inflammatory Mediators in Human Gingival Fibroblasts International Journal of Molecular Sciences, 2023-02-07;24(4):. 2023-02-07 [PMID: 36834667] (Bioassay, Human)
• V Talianová, Z Kejík, R Kaplánek, K Veselá, N Abramenko, L Lacina, K Strnadová, B Dvo?ánková, P Martásek, M Masa?ík, MH Megová, P Bušek, J K?ížová, L Zdražilová, H Hansíková, E Vl?ák, V Filimonenk, A Šedo, K Smetana, M Jakubek New-Generation Heterocyclic Bis-Pentamethinium Salts as Potential Cytostatic Drugs with Dual IL-6R and Mitochondria-Targeting Activity Pharmaceutics, 2022-08-17;14(8):. 2022-08-17 [PMID: 36015338] (Binding Assay, Human)
• M Lindkvist, MM Zegeye, M Grenegård, LU Ljungberg Pleiotropic, Unique and Shared Responses Elicited by IL-6 Family Cytokines in Human Vascular Endothelial Cells International Journal of Molecular Sciences, 2022-01-27;23(3):. 2022-01-27 [PMID: 35163371] (Bioassay, Human)
• D Talwar, J Messens, TP Dick A role for annexin A2 in scaffolding the peroxiredoxin 2-STAT3 redox relay complex Nature Communications, 2020-09-09;11(1):4512. 2020-09-09 [PMID: 32908147] (Bioassay, Human)
• S Kang, T Tanaka, H Inoue, C Ono, S Hashimoto, Y Kioi, H Matsumoto, H Matsuura, T Matsubara, K Shimizu, H Ogura, Y Matsuura, T Kishimoto IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome Proc. Natl. Acad. Sci. U.S.A., 2020-08-21;0(0):. 2020-08-21 [PMID: 32826331] (Bioassay, Cell Culture, Human)
• M Findeisen, TL Allen, DC Henstridge, H Kammoun, AE Brandon, LL Baggio, KI Watt, M Pal, L Cron, E Estevez, C Yang, GM Kowalski, L O'Reilly, C Egan, E Sun, LM Thai, G Krippner, TE Adams, RS Lee, J Grötzinger, C Garbers, S Risis, MJ Kraakman, NA Mellet, J Sligar, ET Kimber, RL Young, MA Cowley, CR Bruce, PJ Meikle, PA Baldock, P Gregorevic, TJ Biden, GJ Cooney, DJ Keating, DJ Drucker, S Rose-John, MA Febbraio Treatment of type 2 diabetes with the designer cytokine IC7Fc Nature, 2019-09-25;574(7776):63-68. 2019-09-25 [PMID: 31554967] (Bioassay, Human)
• P Aryappalli, K Shabbiri, RJ Masad, RH Al-Marri, SM Haneefa, YA Mohamed, K Arafat, S Attoub, O Cabral-Mar, KB Ramadi, MJ Fernandez-, BK Al-Ramadi Inhibition of Tyrosine-Phosphorylated STAT3 in Human Breast and Lung Cancer Cells by Manuka Honey is Mediated by Selective Antagonism of the IL-6 Receptor Int J Mol Sci, 2019-09-05;20(18):. 2019-09-05 [PMID: 31491838] (Bioassay, Insect)
• NE McGregor, M Murat, J Elango, IJ Poulton, EC Walker, B Crimeen-Ir, PWM Ho, JH Gooi, TJ Martin, NA Sims IL-6 exhibits both cis and trans signaling in osteocytes and osteoblasts, but only�trans�signaling promotes bone formation and osteoclastogenesis J. Biol. Chem., 2019-03-28;0(0):. 2019-03-28 [PMID: 30923130] (Bioassay, Mouse)
• S Yamamoto, K Omori, H Mandai, M Nakayama, S Nakagawa, H Kobayashi, T Kunimine, H Yoshimura, K Sakaida, H Sako, S Ibaragi, T Yamamoto, H Maeda, S Suga, S Takashiba Fungal metabolite (+)-terrein suppresses IL-6/sIL-6R-induced CSF1 secretion by inhibiting JAK1 phosphorylation in human gingival fibroblasts Heliyon, 2018-11-26;4(11):e00979. 2018-11-26 [PMID: 30519664] (Bioassay, Human)
• Y Tanaka, L Sabharwal, M Ota, I Nakagawa, JJ Jiang, Y Arima, H Ogura, M Okochi, M Ishii, D Kamimura, M Murakami Presenilin 1 Regulates NF-?B Activation via Association with Breakpoint Cluster Region and Casein Kinase II J. Immunol., 2018-09-10;0(0):. 2018-09-10 [PMID: 30201812] (Bioassay, In Vivo, Mouse)
• M Lyman, V Lieuw, R Richardson, A Timmer, C Stewart, S Granger, R Woods, M Silacci, D Grabulovsk, R Newman A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases J. Biol. Chem., 2018-04-20;0(0):. 2018-04-20 [PMID: 29678878] (Bioassay, Human)
• RL Huang, Y Sun, CK Ho, K Liu, QQ Tang, Y Xie, Q Li IL-6 potentiates BMP-2-induced osteogenesis and adipogenesis via two different BMPR1A-mediated pathways Cell Death Dis, 2018-02-02;9(2):144. 2018-02-02 [PMID: 29396550] (Bioassay, Human)
• H Alsaffar, N Martino, JP Garrett, AP Adam Interleukin-6 promotes a sustained loss of endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation and de novo protein synthesis Am. J. Physiol., Cell Physiol., 2018-01-10;0(0):. 2018-01-10 [PMID: 29351406] (Bioassay, Human)
• AK Ravi, J Plumb, R Gaskell, S Mason, CS Broome, G Booth, M Catley, J Vestbo, D Singh COPD monocytes demonstrate impaired migratory ability Respir. Res., 2017-05-11;18(1):90. 2017-05-11 [PMID: 28494757] (Bioassay, Human)
• JV Larsen, CM Petersen SorLA in interleukin-6 signaling and turnover Mol. Cell. Biol, 2017-05-16;0(0):. 2017-05-16 [PMID: 28265003] (Bioassay, Human)
• Structure-based virtual screening and characterization of a novel IL-6 antagonistic compound from synthetic compound database Drug Des Devel Ther, 2016-12-15;10(0):4091-4100. 2016-12-15 [PMID: 28008232] (Bioassay, Enzyme Assay, Human)
• Angela P Bastidas-C, Astrid D Bakker, Behrouz Zandieh-D, Cornelis J Kleverlaa, Nathalie Bravenboe, Tim Forouzanf, Jenneke Klein-Nul Cytokines TNF-?, IL-6, IL-17F, and IL-4 Differentially Affect Osteogenic Differentiation of Human Adipose Stem Cells. Stem Cells International, 2016-09-07;0(0):1687-966X. 2016-09-07 [PMID: 27667999] (Bioassay, Human)
• Involvement of Spinal IL-6 Trans-Signaling in the Induction of Hyperexcitability of Deep Dorsal Horn Neurons by Spinal Tumor Necrosis Factor-Alpha J Neurosci, 2016-09-21;36(38):9782-91. 2016-09-21 [PMID: 27656018] (Bioassay, Rat)
• STAT3-induced WDR1 overexpression promotes breast cancer cell migration Cell Signal, 2016-08-10;0(0):. 2016-08-10 [PMID: 27521604] (Bioassay, Human)
• Zhong H, Davis A, Ouzounova M, Carrasco R, Chen C, Breen S, Chang Y, Huang J, Liu Z, Yao Y, Hurt E, Moisan J, Fung M, Tice D, Clouthier S, Xiao Z, Wicha M, Korkaya H, Hollingsworth R A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors. Cancer Res, 2016-01-07;76(2):480-90. 2016-01-07 [PMID: 26744529] (Bioassay, Human)
• Bhardwaj R, Yester J, Singh S, Biswas D, Surace M, Waters M, Hauser K, Yao Z, Boyce B, Kordula T RelB/p50 complexes regulate cytokine-induced YKL-40 expression. J Immunol, 2015-02-13;194(6):2862-70. 2015-02-13 [PMID: 25681350] (Bioassay, Human)
• Isobe , Aki, Sawada , Kenjiro, Kinose , Yasuto, Ohyagi-Hara , Chifumi, Nakatsuka , Erika, Makino , Hiroshi, Ogura , Tomonori, Mizuno , Tomoko, Suzuki , Noriko, Morii , Eiichi, Nakamura , Koji, Sawada , Ikuko, Toda , Aska, Hashimoto , Kae, Mabuchi , Seiji, Ohta , Tsuyoshi, Morishige , Ken-ichi, Kurachi , Hirohisa, Kimura , Tadashi Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer. PLoS ONE, 2015-02-06;10(2):e0118080. 2015-02-06 [PMID: 25658637] (Bioassay, Human)
• Sobotta M, Liou W, Stocker S, Talwar D, Oehler M, Ruppert T, Scharf A, Dick T Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling. Nat Chem Biol, 2014-11-24;11(1):64-70. 2014-11-24 [PMID: 25402766] (Bioassay, Human)
• Bu Y, Su F, Wang X, Gao H, Lei L, Chang N, Wu Q, Hu K, Zhu X, Chang Z, Meng K, Xiong J Protein tyrosine phosphatase PTPN9 regulates erythroid cell development through STAT3 dephosphorylation in zebrafish. J Cell Sci, 2014-04-11;127(0):2761-70. 2014-04-11 [PMID: 24727614] (Bioassay, Human)
• Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, Popplewell A, Adams R, Baker T, Rapecki S, Marshall D, Moore A, Neale H, Lawson A Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs, 2014-04-02;6(3):774-82. 2014-04-02 [PMID: 24670876] (Bioassay, Human)
• O'Reilly S, Ciechomska M, Cant R, van Laar J Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-beta (TGF-beta) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J Biol Chem, 2014-02-18;289(14):9952-60. 2014-02-18 [PMID: 24550394] (Bioassay, Human)
• McFarland B, Hong S, Rajbhandari R, Twitty G, Gray G, Yu H, Benveniste E, Nozell S NF-kappaB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma. PLoS ONE, 2013-11-11;8(11):e78728. 2013-11-11 [PMID: 24244348] (Cell Culture, Human)
• Csaszar , Elizabet, Wang , Weijia, Usenko , Tatiana, Qiao , Wenlian, Delaney , Colleen, Bernstein , Irwin D, Zandstra , Peter W Blood stem cell fate regulation by Delta-1-mediated rewiring of IL-6 paracrine signaling. Blood, 2013-11-15;123(5):650-8. 2013-11-15 [PMID: 24243972] (Bioassay, Human)
• Zheng Y, McFarland B, Drygin D, Yu H, Bellis S, Kim H, Bredel M, Benveniste E Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma. Clin Cancer Res, 2013-09-13;19(23):6484-94. 2013-09-13 [PMID: 24036851] (Cell Culture, Human)
• Yoo H, Seo J, Yoo J CTR9, a component of PAF complex, controls elongation block at the c-Fos locus via signal-dependent regulation of chromatin-bound NELF dissociation. PLoS ONE, 2013-04-11;8(4):e61055. 2013-04-11 [PMID: 23593388] (Bioassay, Human)
• Patel A, Zhu Y, Kuzhikandathil E, Banks W, Siegel A, Zalcman S Soluble interleukin-6 receptor induces motor stereotypies and co-localizes with gp130 in regions linked to cortico-striato-thalamo-cortical circuits. PLoS ONE, 2012-07-23;7(7):e41623. 2012-07-23 [PMID: 22911828] (In Vivo, Mouse)
• Narazaki M, Segarra M, Hou X, Tanaka T, Li X, Tosato G Oligo-guanosine nucleotide induces neuropilin-1 internalization in endothelial cells and inhibits angiogenesis. Blood, 2010-07-06;116(16):3099-107. 2010-07-06 [PMID: 20606164] (Neutralization, Human)
• Umehara A, Nishioka M, Obata T A novel ultra-sensitive enzyme immunoassay for soluble human insulin receptor ectodomain and its measurement in urine from healthy subjects and patients with diabetes mellitus. Clin. Biochem., 2009-06-25;42(13):1468-75. 2009-06-25 [PMID: 19560451] (ELISA (Standard))
• Yammani RR, Long D, Loeser RF Interleukin-7 stimulates secretion of S100A4 by activating the JAK/STAT signaling pathway in human articular chondrocytes. Arthritis Rheum., 2009-03-01;60(3):792-800. 2009-03-01 [PMID: 19248116] (Bioassay, Human)
• Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, Groshen SG, Seeger RC, DeClerck YA Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res., 2009-01-01;69(1):329-37. 2009-01-01 [PMID: 19118018] (Bioassay, Human)
• Ahmed S, Marotte H, Kwan K, Ruth JH, Campbell PL, Rabquer BJ, Pakozdi A, Koch AE Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. Proc. Natl. Acad. Sci. U.S.A., 2008-09-16;105(38):14692-7. 2008-09-16 [PMID: 18796608] (Bioassay, Human)
• Ammit AJ, Moir LM, Oliver BG, Hughes JM, Alkhouri H, Ge Q, Burgess JK, Black JL, Roth M Effect of IL-6 trans-signaling on the pro-remodeling phenotype of airway smooth muscle. Am. J. Physiol. Lung Cell Mol. Physiol., 2006-08-25;292(1):L199-206. 2006-08-25 [PMID: 16936245] (Bioassay, Human)
• Mozaffarian D, Rimm EB, King IB, Lawler RL, McDonald GB, Levy WC trans fatty acids and systemic inflammation in heart failure. Am. J. Clin. Nutr., 2004-12-01;80(6):1521-5. 2004-12-01 [PMID: 15585763] (ELISA (Standard))
• Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C CD14 is an acute-phase protein. J. Immunol., 2004-04-01;172(7):4470-9. 2004-04-01 [PMID: 15034063] (Bioassay, Human)
• Hurst SM, McLoughlin RM, Monslow J, Owens S, Morgan L, Fuller GM, Topley N, Jones SA Secretion of oncostatin M by infiltrating neutrophils: regulation of IL-6 and chemokine expression in human mesothelial cells. J. Immunol., 2002-11-01;169(9):5244-51. 2002-11-01 [PMID: 12391243] (ELISA (Standard))
• Erices A, Conget P, Rojas C, Minguell JJ Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. Exp. Cell Res., 2002-10-15;280(1):24-32. 2002-10-15 [PMID: 12372336] (Bioassay, Human)

Bioinformatics

• Gene Symbol: IL6R
• Uniprot:
  • P08887.1()